Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Forty Seven

- PMLiVE

Astellas wins NICE backing for Xtandi in prostate cancer

England’s health guidance body says drug can be used in advanced cases of the disease

- PMLiVE

J&J files HIV combination in Europe

Seeks approval for fixed-dose tablet containing Prezista and Gilead’s cobicistat

- PMLiVE

Kidney cancer campaign launches in UK

The ‘Be Clear on Cancer’ campaign is aimed at raising awareness of the symptoms of bladder and kidney cancers

- PMLiVE

Merck’s vintafolide shows its worth in ovarian cancer

Phase II data shows improvement on current oncology treatments

- PMLiVE

Boehringer files nintedanib for lung cancer in Europe

Pharma company seeks approval for second oncology drug

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

- PMLiVE

Lilly enters cancer collaboration in China

Signs deal with Chi-Med to develop and commercialise fruquintinib

Bayer symbol

Bayer expects five drugs to enter phase III in 2015

Hopes to follow success of recent launches

- PMLiVE

FDA gives green light to Roche for early Perjeta in breast cancer

Oncology drug can now be used before surgery in the US

- PMLiVE

UK breast cancer campaign tackles confidence failings

Breast Cancer Care aims to address negative impact on how women feel about their bodies

- PMLiVE

AZ moves closer to EU approval for ovarian cancer drug

Olaparib on course to be first PARP inhibitor available for ovarian cancer

- PMLiVE

ECC 2013: Nintedanib data boosts Boehringer’s oncology ambitions

Lung cancer drug shows extended overall survival in adenocarcinoma patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links